JP Morgan Maintains Neutral on Editas Medicine, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng has maintained a Neutral rating on Editas Medicine (NASDAQ:EDIT) and raised the price target from $8 to $9.
February 27, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has maintained a Neutral rating on Editas Medicine and increased the price target from $8 to $9.
The increase in price target by JP Morgan suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100